Metropolitan Life Insurance Company (MetLife)’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-3,638
| Closed | -$321K | – | 2300 |
|
|
2021
Q4 | $321K | Buy |
3,638
+10
| +0.3% | +$825 | ﹤0.01% | 1704 |
|
|
2021
Q3 | $280K | Sell |
3,628
-145
| -4% | -$11.4K | ﹤0.01% | 1827 |
|
|
2021
Q2 | $315K | Sell |
3,773
-8,476
| -69% | -$672K | ﹤0.01% | 1824 |
|
|
2021
Q1 | $925K | Sell |
12,249
-523
| -4% | -$42.7K | 0.01% | 995 |
|
|
2020
Q4 | $1.12M | Sell |
12,772
-253
| -2% | -$20.1K | 0.02% | 803 |
|
|
2020
Q3 | $991K | Sell |
13,025
-333
| -2% | -$33.7K | 0.02% | 749 |
|
|
2020
Q2 | $1.65M | Buy |
13,358
+822
| +7% | +$81.7K | 0.03% | 476 |
|
|
2020
Q1 | $1.06M | Sell |
12,536
-395
| -3% | -$34K | 0.02% | 653 |
|
|
2019
Q4 | $1.09M | Sell |
12,931
-241
| -2% | -$18.2K | 0.02% | 845 |
|
|
2019
Q3 | $888K | Buy |
13,172
+158
| +1% | +$12.2K | 0.02% | 922 |
|
|
2019
Q2 | $1.11M | Sell |
13,014
-300
| -2% | -$25.7K | 0.02% | 832 |
|
|
2019
Q1 | $1.18M | Sell |
13,314
-279
| -2% | -$25.9K | 0.02% | 792 |
|
|
2018
Q4 | $1.16M | Sell |
13,593
-44
| -0.3% | -$4.19K | 0.02% | 723 |
|
|
2018
Q3 | $1.32M | Sell |
13,637
-272
| -2% | -$27.2K | 0.02% | 773 |
|
|
2018
Q2 | $1.31M | Buy |
13,909
+861
| +7% | +$75.4K | 0.02% | 788 |
|
|
2018
Q1 | $1.06M | Buy |
13,048
+3
| +0% | +$257 | 0.01% | 875 |
|
|
2017
Q4 | $1.16M | Sell |
13,045
-122
| -0.9% | -$10.6K | 0.02% | 821 |
|
|
2017
Q3 | $1.23M | Buy |
13,167
+671
| +5% | +$59.3K | 0.01% | 1138 |
|
|
2017
Q2 | $1.14M | Buy |
12,496
+763
| +7% | +$69.4K | 0.01% | 1177 |
|
|
2017
Q1 | $1.03M | Hold |
11,733
| – | – | 0.01% | 1222 |
|
|
2016
Q4 | $972K | Sell |
11,733
-529
| -4% | -$45.5K | 0.01% | 1307 |
|
|
2016
Q3 | $1.13M | Buy |
12,262
+48
| +0.4% | +$4.52K | 0.01% | 1214 |
|
|
2016
Q2 | $950K | Buy |
12,214
+195
| +2% | +$16.6K | 0.01% | 1287 |
|
|
2016
Q1 | $991K | Hold |
12,019
| – | – | 0.01% | 1182 |
|
|
2015
Q4 | $1.26M | Buy |
12,019
+322
| +3% | +$33.6K | 0.01% | 1068 |
|
|
2015
Q3 | $1.23M | Hold |
11,697
| – | – | 0.01% | 1087 |
|
|
2015
Q2 | $1.6M | Buy |
11,697
+617
| +6% | +$76.5K | 0.01% | 1050 |
|
|
2015
Q1 | $1.38M | Buy |
11,080
+795
| +8% | +$84.2K | 0.01% | 1037 |
|
|
2014
Q4 | $930K | Buy |
10,285
+274
| +3% | +$22.8K | 0.01% | 1364 |
|
|
2014
Q3 | $722K | Sell |
10,011
-75
| -0.7% | -$4.93K | 0.01% | 1477 |
|
|
2014
Q2 | $627K | Buy |
10,086
+523
| +5% | +$31.6K | ﹤0.01% | 1668 |
|
|
2014
Q1 | $652K | Hold |
9,563
| – | – | ﹤0.01% | 1619 |
|
|
2013
Q4 | $672K | Hold |
9,563
| – | – | ﹤0.01% | 1611 |
|
|
2013
Q3 | $691K | Sell |
9,563
-128
| -1% | -$8.51K | 0.01% | 1535 |
|
|
2013
Q2 | $541K | Buy |
+9,691
| New | +$604K | ﹤0.01% | 1645 |
|
Other funds holding BMRN
BBA
Metropolitan Life Insurance Company (MetLife)'s BMRN Position: Q1 2022 in Review
Metropolitan Life Insurance Company (MetLife) sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 3,638 shares — an estimated $321K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in BMRN in Q2 2013 and held it in 35 quarters. The position peaked at $1.65M in Q2 2020. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.
- Metropolitan Life Insurance Company (MetLife) reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 3,638 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $321K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 35 quarters.
- Metropolitan Life Insurance Company (MetLife)'s BioMarin Pharmaceuticals position peaked at $1.65M in Q2 2020.
- 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.